Clinical Trials – Surufatinib for Neuroendocrine Cancer
What is Surufatinib?Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Its unique dual mechanism of action may be very suitable for possible combinations with other immunotherapies, where there may be synergistic anti-tumor effects. Update 17th November 2021. Interim findings from a phase 1 dose-escalation and dose-expansion study, which were presented during the 2021 NANETS Symposium, demonstrated antitumor activity with surufatinib in heavily pretreated, United States-based patients with progressive NETs. Moreover, the data were consistent with 2 completed phase 3 studies that were performed with surufatinib in Chinese…
